Skip to main content

Table 1 Patients’ demographic and baseline clinical characteristics (n = 89)

From: Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Characteristic Count (%)
Gender, n (%)
  Male 45 (49)
  Female 44 (51)
Age, n (%)
  < 60 years 57 (64)
  ≥ 60 years 32 (36)
Race, n (%)
  Non-Hispanic White 63 (71)
  African-American 18 (20)
  Hispanic 8 (9)
Performance status, n (%)
  0 35 (39)
  1 49 (55)
  2 5 (6)
Histological grade
  Well 3 (3)
  Moderate 69 (78)
  Poor 17 (19)
Number of metastatic sites
< 3 42 (47)
≥ 3 47 (53)
Serum albumin
  Normal 72 (81)
  Low (<3.5 g/dL) 17 (19)
Serum LDH
  Normal 19 (21)
  Elevated (>618 IU/L) 70 (79)
RMH Score
  < 2 43 (48)
  ≥ 2 46 (52)
KRAS exon 2 wild-typea 89 (100)
  KRAS non-exon 2 mutations (n = 70) 0
  NRAS mutations (n = 23) 0
  BRAF V600E mutation (n = 64) 0
  PIK3CA mutations (n = 37) 6
  1. aKRAS exon 2 wild-type status included codons 12 and 13 (exon 2); non-exon 2 KRAS mutations included exon 3 in 55 cases and exon 3 + 4 in 15 cases; NRAS mutations included exons 2 in 23, exon 3 in 17 and exon 4 in 6; PIK3CA mutations included hotspots within exons 9 and 20
Back to article page